タフェノキン

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Warning

• 危険有害性情報

  H302：飲み込むと有害

  H315：皮膚刺激

  H319：強い眼刺激

  H335：呼吸器への刺激のおそれ

• 注意書き

  P261：粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。

  P305+P351+P338：眼に入った場合：水で数分間注意深く洗うこと。次にコ ンタクトレンズを着用していて容易に外せる場合は外す こと。その後も洗浄を続けること。

タフェノキン 化学特性,用途語,生産方法

• 効能

  抗マラリア薬

• 使用

  Tafenoquine is a pharmaceutical developed for the treatment of Plasmodium vivax malaria. Tafenoquine is also being explored for pharmaceutical use for inhibition of Toxoplasma gondii growth.

• 応用例（製薬）

  Etaquine. A synthetic 8-aminoquinoline, formulated as the succinate for oral administration. Tafenoquine is an effective schizonticide against P. falciparum and P. vivax. It is also active against the pre-erythrocytic stages of these species and the hypnozoites of P. vivax. A dosage of 100 mg base corresponds to 125 mg salt. Oral absorption is slow with a maximum plasma concentration reached after 12 h. The half-life is 2 weeks, significantly longer than that of primaquine. It is not eliminated via the kidneys. Toxicity and side effects are similar to those of primaquine. Development of methemoglobinemia is common. Patients with G6PD deficiency may develop severe hemolysis.
  It is in clinical development for the treatment and prophylaxis of P. vivax malaria and for the treatment of P. falciparum infection.

タフェノキン 生産企業

Global(35)Suppliers